Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
18.54 AUD | -1.64% | -1.90% | -25.67% |
Apr. 24 | Neuren Pharmaceuticals Posts AU$243 Million Cash, Short-Term Investments | MT |
Apr. 23 | Neuren Pharmaceuticals' Medication Secures Priority Review from Health Canada | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-25.67% | 1.56B | |
+24.17% | 562B | |
-6.33% | 358B | |
+19.90% | 322B | |
+7.95% | 297B | |
+13.45% | 219B | |
+6.04% | 199B | |
-10.51% | 196B | |
-12.26% | 149B | |
-6.47% | 146B |
- Stock Market
- Equities
- NEU Stock
- News Neuren Pharmaceuticals Limited
- Neuren Pharmaceuticals' : US Partner to Conduct Trofinetide Clinical Study in Rett Syndrome Patients